4 news items
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
SRZN
10 Jun 24
of joint research, Boehringer Ingelheim will assume all development and commercial responsibilities. About Wnt Signaling
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
SRZN
4 Jun 24
Ingelheim will assume all development and commercial responsibilities. About Wnt SignalingWnt signaling plays key roles
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
SRZN
9 May 24
research, Boehringer Ingelheim will assume all development and commercial responsibilities. About Wnt SignalingWnt
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
SRZN
3 Apr 24
, Boehringer Ingelheim will assume all development and commercial responsibilities. About Wnt SignalingWnt signaling
- Prev
- 1
- Next